3 ms·
There's individual data, too. [1] There's a lot of data coming out about this and it's pretty much a trade-off. You get more people some level of immunity, redu
by arcticbull 6y ago
There's individual data, too. [1] There's a lot of data coming out about this and it's pretty much a trade-off. You get more people some level of immunity, reducing spread, and you improve the quality of the immunity with a delayed dose vs. immediate turn.
The results of this primary analysis of two doses of ChAdOx1 nCoV-19 were consistent with those seen in the interim analysis of the trials and confirm that the vaccine is efficacious, with results varying by dose interval in exploratory analyses. A 3-month dose interval might have advantages over a programme with a short dose interval for roll-out of a pandemic vaccine to protect the largest number of individuals in the population as early as possible when supplies are scarce, while also improving protection after receiving a second dose.
There's a lot of work going on now to study this, and the results coming out are all pointing at this being a pretty good path forward.
[1] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6...